No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation operates as a subsidiary of Medigen Biotechnology Corp.
www.medigenvac.comNo one on the platform currently holds 6547.TWO.
No tracked institution reports a position in 6547.TWO as of their last filing.
No one on the platform has traded 6547.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 1.2% | 121.5% | ||||
| Profit Margin % | -45.9% | -145.0% | ||||
| Free Cash Flow Margin % | -16.3% | -95.0% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $780M | +12.2% | $0.25 | $0.25–$0.25 | — | 1 |
| 2027 | $1.3B | +71.8% | $1.58 | $1.58–$1.58 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $0.06 | $0.07 | +16.7% |
| 2026-05-08 | $0.03 | $-0.09 | -400.0% |
| 2026-03-13 | $0.09 | $-0.42 | -566.7% |
| 2025-11-06 | $0.07 | $-0.07 | -200.0% |
| 2025-08-06 | $0.08 | $-0.30 | -475.0% |
| 2025-05-09 | $0.08 | $-0.06 | -175.0% |
| 2025-03-05 | $-0.01 | $-0.07 | -600.0% |
| 2024-11-04 | $-0.32 | $0.00 | +101.4% |
| $129.50 |
| -1.15% |
| $12.4B |
| — |
| 6541.TWTanvex BioPharma, Inc. | $30.55 | +0.83% | $8.1B | — |
| 6576.TWOForesee Pharmaceuticals Co., Ltd. | $82.80 | +1.10% | $13.0B | — |
Source: Financial Modeling Prep · peers by sector/industry